EP4377314A4 - Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation - Google Patents

Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation

Info

Publication number
EP4377314A4
EP4377314A4 EP22850242.3A EP22850242A EP4377314A4 EP 4377314 A4 EP4377314 A4 EP 4377314A4 EP 22850242 A EP22850242 A EP 22850242A EP 4377314 A4 EP4377314 A4 EP 4377314A4
Authority
EP
European Patent Office
Prior art keywords
bicyclic
making
methods
pgdh inhibitors
pgdh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22850242.3A
Other languages
German (de)
English (en)
Other versions
EP4377314A1 (fr
Inventor
Sundeep Dugar
Bruce Fahr
Roopa Rai
Michael J. Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Epirium Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epirium Bio Inc filed Critical Epirium Bio Inc
Publication of EP4377314A1 publication Critical patent/EP4377314A1/fr
Publication of EP4377314A4 publication Critical patent/EP4377314A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22850242.3A 2021-07-28 2022-07-27 Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation Pending EP4377314A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226673P 2021-07-28 2021-07-28
US202163226671P 2021-07-28 2021-07-28
PCT/US2022/038515 WO2023009618A1 (fr) 2021-07-28 2022-07-27 Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
EP4377314A1 EP4377314A1 (fr) 2024-06-05
EP4377314A4 true EP4377314A4 (fr) 2025-06-18

Family

ID=85087971

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22850242.3A Pending EP4377314A4 (fr) 2021-07-28 2022-07-27 Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation

Country Status (2)

Country Link
EP (1) EP4377314A4 (fr)
WO (1) WO2023009618A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220146458A (ko) 2020-01-23 2022-11-01 마이오포르테 테라퓨틱스 인코포레이티드 Pgdh 억제제 및 그의 제조 및 사용 방법
EP4655301A1 (fr) * 2023-01-25 2025-12-03 Epirium Bio Inc. Inhibiteurs de pgdh et leurs procédés de fabrication et d'utilisation
WO2025155638A1 (fr) * 2024-01-16 2025-07-24 Epirium Bio Inc. Compositions et méthodes de traitement de l'obésité et du diabète à l'aide d'inhibiteurs de 15-pgdh

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2013123215A2 (fr) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Médicaments antiviraux pour le traitement d'infections à arénavirus
WO2021151014A1 (fr) * 2020-01-23 2021-07-29 Myoforte Therapeutics, Inc. Inhibiteurs pgdh et leurs procédés de fabrication et d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524800A (ja) * 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
EP3917911A1 (fr) * 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. Inhibiteurs de 15-pgdh
EP3982957A4 (fr) * 2019-06-11 2023-06-21 The Board of Trustees of the Leland Stanford Junior University Méthodes de rajeunissement de tissus âgés par l'inhibition de la 15-hydroxyprostaglandine déshydrogénase (15-pgdh)
WO2022082009A1 (fr) * 2020-10-15 2022-04-21 Epirium Bio Inc. Formulations inhalées d'inhibiteurs de pgdh et leurs procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2013123215A2 (fr) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Médicaments antiviraux pour le traitement d'infections à arénavirus
WO2021151014A1 (fr) * 2020-01-23 2021-07-29 Myoforte Therapeutics, Inc. Inhibiteurs pgdh et leurs procédés de fabrication et d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUVEAU DAMIEN Y. ET AL: "Structure-activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 2, 1 January 2014 (2014-01-01), Amsterdam NL, pages 630 - 635, XP093256163, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.11.081 *
OUVRY GILLES ET AL: "Discovery of phenoxyindazoles and phenylthioindazoles as ROR[gamma] inverse agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 23, 12 October 2016 (2016-10-12), pages 5802 - 5808, XP029815424, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.10.023 *
See also references of WO2023009618A1 *

Also Published As

Publication number Publication date
EP4377314A1 (fr) 2024-06-05
WO2023009618A1 (fr) 2023-02-02

Similar Documents

Publication Publication Date Title
EP4377314A4 (fr) Inhibiteurs de pgdh bicycliques et leurs procédés de fabrication et d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
MA54758A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP4236990A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3920772A4 (fr) Spéculum multicouche et ses procédés de fabrication et d'utilisation
EP4284365A4 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
EP4125831A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3917508A4 (fr) Activateurs de la mitofusine et leurs procédés d'utilisation
EP3924159A4 (fr) Ancres ventouses et leurs procédés de fabrication
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3959334A4 (fr) Compositions d'hybridation et leurs procédés de fabrication et d'utilisation
EP4255399A4 (fr) Compositions semi-solides inhibitrices de ped5 et leurs procédés de fabrication et d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP4175624A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP4267133A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP4211233A4 (fr) Compositions et leurs procédés d'utilisation
EP3630772A4 (fr) Procédés de fabrication et d'utilisation d'inhibiteurs de pde9
EP4164653A4 (fr) Formes morphiques de trilaciclib et leurs procédés de fabrication
EP3965776A4 (fr) Compositions oligosaccharidiques et leurs procédés d'utilisation
EP4223500A4 (fr) Stratifié et procédé d'utilisation de stratifié
MA56545A (fr) Inhibiteurs allostériques d'egfr et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/08 20060101ALI20250513BHEP

Ipc: A61K 31/454 20060101ALI20250513BHEP

Ipc: C07D 401/06 20060101ALI20250513BHEP

Ipc: C07D 401/14 20060101ALI20250513BHEP

Ipc: C07D 471/04 20060101AFI20250513BHEP